News Releases

Jan 11, 2021
Myriad Genetics Forms Strategic Partnership with Illumina in Oncology
Products
Jan 08, 2021
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®
Products
Dec 11, 2020
New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations
Pipeline
Nov 17, 2020
Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression
Products
Nov 16, 2020
Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China
Pipeline
Nov 11, 2020
New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis
Pipeline
Oct 16, 2020
German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test
Pipeline
Aug 21, 2020
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
Pipeline
Aug 10, 2020
New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions
Pipeline
Jul 31, 2020
Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer
Pipeline
Jul 29, 2020
Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test
Pipeline
Jul 28, 2020
Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®
Pipeline
Jul 07, 2020
Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk Prediction
Products
Jul 06, 2020
Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer Patients
Products
Jul 01, 2020
Myriad Launches New GeneSight® Psychotropic Patient Collection Kit
Products